255 related articles for article (PubMed ID: 31443436)
1. Organometallic Compounds and Metal Complexes in Current and Future Treatments of Inflammatory Bowel Disease and Colorectal Cancer-a Critical Review.
Szczepaniak A; Fichna J
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31443436
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer and inflammatory bowel diseases: effects of diet and antioxidants.
Carini F; Tomasello G; Jurjus A; Geagea A; Al Kattar S; Damiani P; Sinagra E; Rappa F; David S; Cappello F; Mazzola M; Leone A
J Biol Regul Homeost Agents; 2017; 31(3):791-795. PubMed ID: 28726358
[TBL] [Abstract][Full Text] [Related]
3. The Role of Cyclophilins in Inflammatory Bowel Disease and Colorectal Cancer.
Liang L; Lin R; Xie Y; Lin H; Shao F; Rui W; Chen H
Int J Biol Sci; 2021; 17(10):2548-2560. PubMed ID: 34326693
[TBL] [Abstract][Full Text] [Related]
4. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development.
Waldner MJ; Neurath MF
Semin Immunol; 2014 Feb; 26(1):75-9. PubMed ID: 24447345
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological control of autophagy: therapeutic perspectives in inflammatory bowel disease and colorectal cancer.
García-Mauriño S; Alcaide A; Domínguez C
Curr Pharm Des; 2012; 18(26):3853-73. PubMed ID: 22632751
[TBL] [Abstract][Full Text] [Related]
6. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes.
Tomasello G; Tralongo P; Damiani P; Sinagra E; Di Trapani B; Zeenny MN; Hussein IH; Jurjus A; Leone A
World J Gastroenterol; 2014 Dec; 20(48):18121-30. PubMed ID: 25561781
[TBL] [Abstract][Full Text] [Related]
7. Encapsulation of Polyphenolic Compounds Based on Hemicelluloses to Enhance Treatment of Inflammatory Bowel Diseases and Colorectal Cancer.
Caban M; Lewandowska U
Molecules; 2023 May; 28(10):. PubMed ID: 37241929
[TBL] [Abstract][Full Text] [Related]
8. Role of MiRNAs in Inflammatory Bowel Disease.
Cao B; Zhou X; Ma J; Zhou W; Yang W; Fan D; Hong L
Dig Dis Sci; 2017 Jun; 62(6):1426-1438. PubMed ID: 28391412
[TBL] [Abstract][Full Text] [Related]
9. Bioengineered Colorectal Cancer Drugs: Orally Delivered Anti-Inflammatory Agents.
Urbanska AM; Zhang X; Prakash S
Cell Biochem Biophys; 2015 Jul; 72(3):757-69. PubMed ID: 27352189
[TBL] [Abstract][Full Text] [Related]
10. [The role of cysteinyl leukotrienes in chronic inflammation and neoplasia of the intestine].
Broom OJ; Nielsen OH
Ugeskr Laeger; 2009 Jan; 171(4):243-6. PubMed ID: 19174041
[TBL] [Abstract][Full Text] [Related]
11. Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions - Single institution experience.
Kamarádová K; Vošmiková H; Rozkošová K; Ryška A; Tachecí I; Laco J
Pathol Res Pract; 2019 Apr; 215(4):730-737. PubMed ID: 30679085
[TBL] [Abstract][Full Text] [Related]
12. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X; Ma J; Wang K; Zhang H
Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
[TBL] [Abstract][Full Text] [Related]
13. Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development.
Azer SA
Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):271-81. PubMed ID: 23169309
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer.
Laurent C; Svrcek M; Flejou JF; Chenard MP; Duclos B; Freund JN; Reimund JM
Inflamm Bowel Dis; 2011 Jan; 17(1):232-40. PubMed ID: 20815042
[TBL] [Abstract][Full Text] [Related]
15. Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
Lopez A; Collet-Fenetrier B; Belle A; Peyrin-Biroulet L
J Dig Dis; 2016 Jun; 17(6):383-91. PubMed ID: 27129893
[TBL] [Abstract][Full Text] [Related]
16. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities.
Motilva V; Talero E; Calvo JR; Villegas I; Alarcón-de-la-Lastra C; Sánchez-Fidalgo S
Curr Pharm Des; 2008; 14(1):71-95. PubMed ID: 18220820
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease.
Goessling W; Mayer RJ
Gastroenterol Clin North Am; 2006 Sep; 35(3):713-27. PubMed ID: 16952747
[TBL] [Abstract][Full Text] [Related]
18. Serum immunoinflammation-related protein complexes discriminate between inflammatory bowel disease and colorectal cancer.
Sun YH; Li J; Shu HJ; Li ZL; Qian JM
Clin Transl Oncol; 2019 Dec; 21(12):1680-1686. PubMed ID: 30955196
[TBL] [Abstract][Full Text] [Related]
19. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress and antioxidants in intestinal disease.
Thomson A; Hemphill D; Jeejeebhoy KN
Dig Dis; 1998; 16(3):152-8. PubMed ID: 9618134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
